Samsung Bioepis announced that it has entered into a Strategic Collaboration Agreement with Takeda Pharmaceutical Company to co-develop novel biologic therapies in unmet disease areas.  The companies’ first therapeutic candidate is intended to treat severe acute pancreatitis.

According to the press release, diversifying into novel biologics development represents “a new chapter” for Samsung Bioepis, and the company will continue to advance its pipeline of biosimilar candidates.